Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A pan-cancer single-cell landscape of tumor-infiltrating myeloid cells

ABSTRACT: A pan-cancer single-cell landscape of tumor-infiltrating myeloid cells

PROVIDER: PRJNA647394 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

A pan-cancer single-cell landscape of tumor-infiltrating myeloid cells

Project description:Tumor-infiltrating myeloid cells (TIMs) have emerged as key regulators in tumor progression, however, the similarity and discrepancy of the fundamental properties of these cells across different cancer types remain elusive. Here, we performed a pan-cancer analysis of TIM sub-populations in multiple human cancer types. Our comprehensive analyses provide valuable insights for understanding the TIM properties across multiple tumors.

2021-02-04 | GSE154763 | GEO

Pan-Cancer Single Cell Landscape of Tumor-Infiltrating T Cells

Project description:Pan-Cancer Single Cell Landscape of Tumor-Infiltrating T Cells

| PRJNA658913 | ENA

TREM1 deficiency alters the tumor myeloid landscape

Project description:To comprehensively characterize the impact of TREM1 deficiency specifically within the tumor myeloid populations, we selectively enriched the CD45+CD11b+ tumor-infiltrating myeloid cells from tumor-bearing Trem1+/+ and Trem1-/- mice for scRNA-seq analysis.

2023-09-27 | E-MTAB-13246 | biostudies-arrayexpress

Epigenetic landscape remodeled by the transcription factor RBPJ promotes tumor-infiltrating T cell exhaustion

Project description:Epigenetic landscape remodeled by the transcription factor RBPJ promotes tumor-infiltrating T cell exhaustion

2024-06-18 | PXD053189 | iProX

Pan-Cancer Single Cell Landscape of Tumor-Infiltrating T Cells

Project description:T cells present diverse states in the tumor, playing a central role in cancer immunity and immunotherapies. However, their heterogeneity, dynamics and composition within tumors of various cancer types are not fully characterized. Integrating a pan-cancer single-cell RNA sequencing atlas of T cells cross multiple cancer types, we systematically characterized their diversity, identified the potentially tumor-reactive T cells, and revealed new cell types. Our findings provide new insights into T cell immunity and will facilitate immunotherapy development targeting T cells in human cancer.

2021-12-16 | GSE156728 | GEO

HDACi Delivery Reprograms Tumor-infiltrating Myeloid Cells to Eliminate Antigen-loss Variants

Project description:Immune recognition of tumor-expressed antigens by cytotoxic CD8+ T lymphocytes is the foundation of adoptive T-cell therapy. However, therapy-induced selective pressure can sculpt the antigenicity of tumors resulting in the outgrowth of variants that have lost the target antigen. Interestingly, tumor relapse resulting from adoptive memory T cell transfer and boosting oncolytic viral vaccination can be prevented using Class I histone deacetylase inhibitor, MS-275. We demonstrate that concomitant drug delivery subverts the phenotype and suppressive function of tumor-infiltrating myeloid cells and reprograms them with the cytotoxic capacity to directly eliminate antigen-negative tumor cells. By enhancing the production of IFNγ within the tumor microenvironment, our data suggest that MS-275 modifies the local cytokine landscape in favor of antitumor myeloid cell polarization.

2017-07-28 | GSE101985 | GEO

Gene expression data from CD11b-positive myeloid cells infiltrating tumors after local irradiation

Project description:Analysis of global gene expression in myeloid cells infiltrating tumors after irradiation. Cell death induces recruitment of myeloid cells into irradiated tumors thereby stimulating tumor recurrence. Results provide insights into molecular mechanisms regulating tumorigenic functions of myeloid cells in tumors re-growing after radiation therapy. Samples were collected at day 4 from irradiated tumors in WT, TLR9KO and Stat3KO (MxCre/Stat3flox). There were total 11 samples with 3-4 replicates of each sample type.

2013-12-31 | E-GEOD-45180 | biostudies-arrayexpress

Mouse colon tumor gene expression of epithelial, stromal and infiltrating myeloid cells.

Project description:Mouse colon tumor gene expression of epithelial, stromal and infiltrating myeloid cells.

| PRJNA523582 | ENA

Non-cancerous liver infiltrating lymphocytes of hepatitis C and tumor-infiltrating lymphocytes

Project description:Study goal is to disclose features of gene expressio profile of non-cancerous liver-infiltrating lymphocytes of type C hepatitis patients with hepatocellular carcinomas and tumor-infiltrating lymphocytes of type C hepatitis patients with hepatocellular carcinomas. Keywords: gene expression profile, non-cancerous liver-infiltrating lymphocytes, tumor-infiltrating lymphocytes, type C hepatitis, hepatocellular carcinoma Non-cancerous liver-infiltrating lymphocytes were obtained by laser capture microdissection from surgically resected liver tissues of 12 type C hepatitis patients with hepatocellular carcinoma. The mRNA was amplified and expression profile was comprehensively analyzed with reference RNA using oligo-DNA chip. Tumor-infiltrating lymphocytes were obtained by laser capture microdissection from surgically resected cancer tissues of 12 type C hepatitis patients with hepatocellular carcinoma. The mRNA was amplified and expression profile was comprehensively analyzed with reference RNA using oligo-DNA chip.

2010-06-25 | E-GEOD-10461 | biostudies-arrayexpress

TREM2 blockade modifies the tumor myeloid landscape enhancing anti-PD-1 immunotherapy

Project description:Checkpoint immunotherapy unleashes T cell effector functions that control tumor growth, but can be undermined by myeloid cells that induce immunosuppression. TREM2 is a myeloid surface receptor that binds lipids and transmits intracellular signals through protein-tyrosine phosphorylation known to sustain microglial responses during Alzheimer’s disease. Intriguingly, TREM2 expression has recently been noted in tumor-infiltrating macrophages. We found that Trem2–/– mice are more resistant to growth of sarcoma, colorectal and mammary cancer cells than wild-type mice and are more responsive to anti-PD-1 immunotherapy. Furthermore, treatment with anti-TREM2 mAb curbed tumor growth and led to complete tumor regression when combined with anti-PD-1. scRNA-seq revealed that both constitutive TREM2 deficiency and anti-TREM2 are associated with relatively scant representation of MRC1+ and CX3CR1+ subsets in the macrophage tumor infiltrate, paralleled by expansion of subsets expressing immunostimulatory molecules. These changes were associated with improved T cell responses. TREM2 expression was evident in tumor macrophages in over 200 human cancer cases examined and inversely correlated with prolonged survival for two types of cancer. Thus, TREM2 is a promising target to modify tumor-infiltrating myeloid cells and effectively augment checkpoint immunotherapy.

2020-08-13 | GSE151710 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data